The Role of Gender in Juvenile Idiopathic Arthritis-Associated Uveitis

Journal of Ophthalmology (Impact Factor: 1.43). 02/2014; 2014(2):461078. DOI: 10.1155/2014/461078
Source: PubMed


Uveitis is a common complication of juvenile idiopathic arthritis (JIA) affecting up to 30% of patients with JIA. Although the typical bilateral chronic anterior uveitis associated with the persistent and extended oligoarticular and polyarticular, rheumatoid factor negative variants of JIA occurs predominantly in girls, boys may be more commonly affected in the HLA-B27 positive, enthesitis variant of JIA. While female gender has been associated with the development of the chronic anterior uveitis in children with JIA, the clinical course of JIA-associated uveitis may be worse in boys than in girls. The purpose of this paper is to review the available published literature to determine the role of gender in the clinical presentation and outcomes of patients with JIA-associated uveitis.

Download full-text


Available from: Ahmadreza Moradi, Mar 24, 2014
  • Source

    Jama Ophthalmology 03/2015; 133(5). DOI:10.1001/jamaophthalmol.2015.221 · 3.32 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Uveitis is a potentially sight-threatening complication of juvenile idiopathic arthritis (JIA). JIA-associated uveitis is recognized to have an autoimmune aetiology characterized by activation of CD4(+) T cells, but the underlying mechanisms might overlap with those of autoinflammatory conditions involving activation of innate immunity. As no animal model recapitulates all the features of JIA-associated uveitis, questions remain regarding its pathogenesis. The most common form of JIA-associated uveitis is chronic anterior uveitis, which is usually asymptomatic initially. Effective screening is, therefore, essential to detect early disease and commence treatment before the development of visually disabling complications, such as cataracts, glaucoma, band keratopathy and cystoid macular oedema. Complications can result from uncontrolled intraocular inflammation as well as from its treatment, particularly prolonged use of high-dose topical corticosteroids. Accumulating evidence supports the early introduction of systemic immunosuppressive drugs, such as methotrexate, as steroid-sparing agents. Prospective randomized controlled trials of TNF inhibitors and other biologic therapies are underway or planned. Future research should aim to identify biomarkers to predict which children are at high risk of developing JIA-associated uveitis or have a poor prognosis. Such biomarkers could help to ensure that patients receive earlier interventions and more-potent therapy, with the ultimate aim of reducing loss of vision and ocular morbidity.
    Nature Reviews Rheumatology 03/2015; 11(6). DOI:10.1038/nrrheum.2015.20 · 9.85 Impact Factor
  • Source

    International ophthalmology clinics 07/2015; 55(3):111-131. DOI:10.1097/IIO.0000000000000072
Show more